The targeted drug delivery market is projected to reach $57.5 billion by 2036, at a CAGR of 16.5% from 2026 to 2036. The growth of this market is primarily fueled by the expanding FDA and EMA approval precedent for antibody-drug conjugates, the commercial-scale validation of lipid nanoparticle platforms, and the rising global cancer burden. Additionally, extension of lipid nanoparticle and other nucleic acid delivery platforms into RNA interference and gene-editing candidates, growing outsourcing of conjugation and formulation manufacturing, and expanding clinical pipelines across solid tumor and hematologic indications are expected to create substantial growth opportunities for market participants.
The key players operating in the targeted drug delivery market are F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca plc (U.K.), Daiichi Sankyo Company, Limited (Japan), Pfizer Inc. (U.S.), Gilead Sciences, Inc. (U.S.), AbbVie Inc. (U.S.), Johnson & Johnson (U.S.), Ipsen S.A. (France), Jazz Pharmaceuticals plc (Ireland), Alnylam Pharmaceuticals, Inc. (U.S.), Arrowhead Pharmaceuticals, Inc. (U.S.), Ionis Pharmaceuticals, Inc. (U.S.), Moderna, Inc. (U.S.), BioNTech SE (Germany), Arbutus Biopharma Corporation (Canada), Halozyme Therapeutics, Inc. (U.S.), Lonza Group AG (Switzerland), ADC Therapeutics SA (Switzerland), Mersana Therapeutics, Inc. (U.S.), and CytomX Therapeutics, Inc. (U.S.).
The targeted drug delivery market study presents historical market data value (2025), estimated current data (2026), and forecasts for 2036. This market is segmented by technology, application, end user, and geography.
Among all the technologies, the Antibody-Drug Conjugates segment is expected to hold a leading share of the targeted drug delivery market in 2026. The dominant position of this segment is primarily attributed to the established regulatory precedent for ADCs, its growing base of approved products across solid tumor and hematologic malignancy indications, and the depth of clinical experience biopharmaceutical developers have accumulated in linker chemistry, payload selection, and antigen target validation. The Lipid Nanoparticle segment, however, is projected to register the highest growth during the forecast period, driven by the platform's demonstrated manufacturing scalability following its central role in messenger RNA vaccine production and its extension into RNA interference and gene-editing therapeutic candidates.
Among all the applications, the Oncology segment is expected to account for the largest share of the targeted drug delivery market in 2026, driven by increasing global cancer incidence, the concentration of approved targeted therapeutics in solid tumor and hematologic malignancy indications, and continued clinical trial investment directed at expanding existing conjugate and nanoparticle products into new tumor types. The Genetic and Rare Disorders segment, meanwhile, is projected to register the highest growth during the forecast period, driven by the extension of lipid nanoparticle and other nucleic acid delivery platforms into gene-editing and RNA interference candidates targeting inherited metabolic and neuromuscular disorders.
Among all the end users, the Hospitals and Specialty Cancer Centers segment is expected to account for the largest share of the market in 2026, driven by the requirement for supervised intravenous administration and infusion monitoring associated with most approved antibody-drug conjugates and liposomal therapeutics. The Contract Research and Manufacturing Organizations segment, however, is projected to register meaningful growth during the forecast period, driven by the technical complexity of conjugation chemistry and lipid nanoparticle formulation leading an increasing share of biopharmaceutical developers to outsource process development and commercial-scale manufacturing.
Among all the geographies, North America is expected to account for the largest share of the targeted drug delivery market in 2026, supported by the concentration of oncology drug approvals through the U.S. FDA, a dense cluster of biopharmaceutical companies advancing antibody-drug conjugate and lipid nanoparticle pipelines, and established reimbursement frameworks for high-cost precision therapeutics. Asia Pacific, however, is projected to grow at the fastest rate during the forecast period, supported by the scale of the region's cancer burden, expanding biologics manufacturing capacity in China, India, South Korea, and Japan, and growing government investment in biotechnology and nanomedicine research infrastructure.
The key players operating in the targeted drug delivery market are F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca plc (U.K.), Daiichi Sankyo Company, Limited (Japan), Pfizer Inc. (U.S.), Gilead Sciences, Inc. (U.S.), AbbVie Inc. (U.S.), Johnson & Johnson (U.S.), Ipsen S.A. (France), Jazz Pharmaceuticals plc (Ireland), Alnylam Pharmaceuticals, Inc. (U.S.), Arrowhead Pharmaceuticals, Inc. (U.S.), Ionis Pharmaceuticals, Inc. (U.S.), Moderna, Inc. (U.S.), BioNTech SE (Germany), Arbutus Biopharma Corporation (Canada), Halozyme Therapeutics, Inc. (U.S.), Lonza Group AG (Switzerland), ADC Therapeutics SA (Switzerland), Mersana Therapeutics, Inc. (U.S.), and CytomX Therapeutics, Inc. (U.S.).
The targeted drug delivery market study presents historical market data value (2025), estimated current data (2026), and forecasts for 2036. This market is segmented by technology, application, end user, and geography.
Among all the technologies, the Antibody-Drug Conjugates segment is expected to hold a leading share of the targeted drug delivery market in 2026. The dominant position of this segment is primarily attributed to the established regulatory precedent for ADCs, its growing base of approved products across solid tumor and hematologic malignancy indications, and the depth of clinical experience biopharmaceutical developers have accumulated in linker chemistry, payload selection, and antigen target validation. The Lipid Nanoparticle segment, however, is projected to register the highest growth during the forecast period, driven by the platform's demonstrated manufacturing scalability following its central role in messenger RNA vaccine production and its extension into RNA interference and gene-editing therapeutic candidates.
Among all the applications, the Oncology segment is expected to account for the largest share of the targeted drug delivery market in 2026, driven by increasing global cancer incidence, the concentration of approved targeted therapeutics in solid tumor and hematologic malignancy indications, and continued clinical trial investment directed at expanding existing conjugate and nanoparticle products into new tumor types. The Genetic and Rare Disorders segment, meanwhile, is projected to register the highest growth during the forecast period, driven by the extension of lipid nanoparticle and other nucleic acid delivery platforms into gene-editing and RNA interference candidates targeting inherited metabolic and neuromuscular disorders.
Among all the end users, the Hospitals and Specialty Cancer Centers segment is expected to account for the largest share of the market in 2026, driven by the requirement for supervised intravenous administration and infusion monitoring associated with most approved antibody-drug conjugates and liposomal therapeutics. The Contract Research and Manufacturing Organizations segment, however, is projected to register meaningful growth during the forecast period, driven by the technical complexity of conjugation chemistry and lipid nanoparticle formulation leading an increasing share of biopharmaceutical developers to outsource process development and commercial-scale manufacturing.
Among all the geographies, North America is expected to account for the largest share of the targeted drug delivery market in 2026, supported by the concentration of oncology drug approvals through the U.S. FDA, a dense cluster of biopharmaceutical companies advancing antibody-drug conjugate and lipid nanoparticle pipelines, and established reimbursement frameworks for high-cost precision therapeutics. Asia Pacific, however, is projected to grow at the fastest rate during the forecast period, supported by the scale of the region's cancer burden, expanding biologics manufacturing capacity in China, India, South Korea, and Japan, and growing government investment in biotechnology and nanomedicine research infrastructure.
Key Questions Answered in the Report:
- What is the current revenue generated by the targeted drug delivery market globally?
- At what rate is the targeted drug delivery market demand projected to grow for the next 10 years?
- What are the historical market sizes and growth rates of the targeted drug delivery market?
- What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
- Which segments in terms of technology, application, and end user are expected to create major traction for the manufacturers in this market?
- What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the manufacturers operating in the targeted drug delivery market?
- Who are the major players in the targeted drug delivery market? What are their specific product offerings in this market?
- What are the recent strategic developments in the targeted drug delivery market? What are the impacts of these strategic developments on the market?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Targeted Drug Delivery Market, by Technology
6. Targeted Drug Delivery Market, by Payload Type
7. Targeted Drug Delivery Market, by Application
8. Targeted Drug Delivery Market, by Route of Administration
9. Targeted Drug Delivery Market, by End User
10. Targeted Drug Delivery Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- AstraZeneca plc
- Daiichi Sankyo Company, Limited
- Pfizer Inc.
- Gilead Sciences, Inc.
- AbbVie Inc.
- Johnson & Johnson
- Ipsen S.A.
- Jazz Pharmaceuticals plc
- Alnylam Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Moderna, Inc.
- BioNTech SE
- Arbutus Biopharma Corporation
- Halozyme Therapeutics, Inc.
- Lonza Group AG
- ADC Therapeutics SA
- Mersana Therapeutics, Inc.
- CytomX Therapeutics, Inc. (U.S.).
